{
    "clinical_study": {
        "@rank": "30255", 
        "arm_group": [
            {
                "arm_group_label": "AMG531 (Dose 1)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "AMG531 (Dose 2)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "AMG531 (Dose 3)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "AMG531 (Dose 4)", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The present study will be conducted to evaluate the efficacy and safety of AMG531 and to\n      determine the recommended initial dose of AMG531 on the basis of its efficacy and safety\n      when it is administered subcutaneously (SC) to the Aplastic Anemia (AA) patients with\n      immunosuppressive-therapy refractory thrombocytopenia and also to assess the\n      pharmacokinetics of this product. Its efficacy and safety during the extension period will\n      also be evaluated."
        }, 
        "brief_title": "A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Aplastic Anemia", 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Anemia, Aplastic", 
                "Thrombocytopenia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient who is diagnosed as AA and refractory to immunosuppressive therapy\n\n          -  Platelet \u2264 30,000/\u03bcL\n\n        Exclusion Criteria:\n\n          -  Concurrent active infection not adequately responding to appropriate therapy\n\n          -  HIV positivity\n\n          -  Bone marrow reticulin grade of > 1\n\n          -  Clinically significant cardiac disease\n\n          -  Arterial or venous thrombosis within the last 1 year before enrollment\n\n          -  Other cause of thrombocytopenia\n\n          -  AA with hemolytic predominant paroxysmal nocturnal hemoglobinuria (PNH)\n\n          -  Uncontrolled diabetes\n\n          -  Receiving any agent used to treat AA, including antithymocyte globulin (ATG) or ATG +\n             cyclosporine within 6 months before starting study treatment and/or cyclosporine or\n             anabolic hormone within 6 weeks before starting the study treatment\n\n          -  History of PEG-rHuMGDF, recombinant human thrombopoietin, AMG531, and other\n             thrombopoietin (TPO)-receptor agonist\n\n          -  Who plans to conduct hematopoietic stem cell transplantation within 1 year"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02094417", 
            "org_study_id": "531-KR001"
        }, 
        "intervention": {
            "arm_group_label": [
                "AMG531 (Dose 3)", 
                "AMG531 (Dose 1)", 
                "AMG531 (Dose 2)", 
                "AMG531 (Dose 4)"
            ], 
            "description": "Subcutaneous, weekly injection", 
            "intervention_name": "AMG531", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Anemia, Aplastic", 
            "Thrombopoietin", 
            "Thrombocytopenia"
        ], 
        "lastchanged_date": "March 20, 2014", 
        "location": [
            {
                "contact": {
                    "email": "clinial.info@kyowa-kirin.co.jp", 
                    "last_name": "Kyowa Hakko Kirin Korea Co., Ltd"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Seoul St. Mary's Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "clinical.info@kyowa-kirin.co.jp", 
                    "last_name": "Kyowa Hakko Kirin Korea Co., Ltd"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }, 
                    "name": "Samsung Medical Center"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 2, Randomized, Open-Label, Parallel, Comparative, Dose-Finding Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia Subjects With Thrombocytopenia Refractory to Immunosuppressive Therapy", 
        "overall_contact": {
            "email": "clinical.info@kyowa-kirin.co.jp", 
            "last_name": "Kyowa Hakko Kirin Korea Co., Ltd"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The proportion of subjects achieving a platelet response", 
            "safety_issue": "No", 
            "time_frame": "At week 9"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02094417"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The proportion of subjects achieving a platelet response", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "measure": "The proportion of subjects who become platelet transfusion independent", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "measure": "The proportion of subjects achieving erythroid response", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "measure": "The proportion of subjects achieving neutrophil response", 
                "safety_issue": "No", 
                "time_frame": "52 Weeks"
            }, 
            {
                "measure": "Changes in Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto (GIMEMA) bleeding scale", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }, 
            {
                "description": "Pharmacokinetic parameters, including time to maximum concentration (Tmax),  maximum concentration (Cmax) and area under the curve (AUC)0-t, will be assessed.", 
                "measure": "Profiles of Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "Weeks 1, 4, and 8"
            }, 
            {
                "measure": "Incidences of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "52 weeks + 4 weeks follow-up"
            }, 
            {
                "measure": "Development of neutralizing antibody", 
                "safety_issue": "No", 
                "time_frame": "52 weeks + 4 weeks follow-up"
            }
        ], 
        "source": "Kyowa Hakko Kirin Korea Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kyowa Hakko Kirin Korea Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}